Adaptive Biotechnologies Corporation (ADPT)

Market Cap	684.27M
Revenue (ttm)	168.77M
Net Income (ttm)	-213.47M
Shares Out	147.47M
EPS (ttm)	-1.47
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	267,302
Open	4.720
Previous Close	4.780
Day's Range	4.640 - 4.750
52-Week Range	2.280 - 6.340
Beta	1.43
Analysts	Buy
Price Target	6.40 (+37.93%)
Earnings Date	Nov 7, 2024

About ADPT

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient’s body during and after treatment, known as M...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 27, 2019
• Employees: 709
• Stock Exchange: NASDAQ
• Ticker Symbol: ADPT
• Website: https://www.adaptivebiotech.com

Financial Performance

In 2023, Adaptive Biotechnologies's revenue was $170.28 million, a decrease of -8.11% compared to the previous year's $185.31 million. Losses were -$225.25 million, 12.5% more than in 2022.

Analyst Forecast

According to 5 analysts, the average rating for ADPT stock is "Buy." The 12-month stock price forecast is $6.4, which is an increase of 37.93% from the latest price.

Price Target

$6.4

(37.93% upside)

Analyst Consensus: Buy